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Conclusion. The most accurate and reliable method for measuring relative dose are ﬁlms. Diodes and MOSFET can be used for
output factor measurements, but corrections must be taken into account. Results are consistent and the ﬁrst clinical results
indicate a favourable evolution.
http://dx.doi.org/10.1016/j.rpor.2013.03.544
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Purpose. In this study we report our ﬁrst clinical results of prostate motion management during stereotactic gated RapidArc
treatment and a novel application, IntrafractionMotion Review (IMR, Varianmedical systems) allowing kV/MV images acquisition
during dose delivery.
Methods and materials. Seven prostate cancer patients were treated using the gated RapidArc technique with a Varian Novalis
Truebeam linear accelerator. Before treatment simulation, three gold ﬁducial markers and Hialuronic Acid were implanted inside
the prostate using transrectal ultrasound guidance. A computed tomography (CT) was registered with a MR acquisition for
simulation. Treatment planning was realized on an Eclipse workstation with PRO 3 algorithm V 10.0.28. Dose delivery consists
on 2 arcs using Rapidarc modality with 600MU/min maximum dose rate on a Novalis Truebeam linear accelerator. An equivalent
dose of 84Gy over 20 fractions at 3.1Gy/fraction was delivered. Before the treatment delivery, the RPM block placed on patient’s
abdominal surface generate the gating signal use for IMR acquisition on V1.6 of Truebeam. Then, the patient’s alignment is set
based on markers using daily cone beam CT (CBCT) and kV/kV matching. During the treatment, kV images were acquired at
each exhale phase of the breathing cycle and the positions of the ﬁducial markers were compared with their expected positions
represented by a green circle with a diameter corresponding to the ﬁducial length. We reported here for the six ﬁrst patients
the differences between expected and real ﬁducial position. The treatment delivery parameters such as number of kV images
acquired per fraction, the fraction’s time and the room occupation’s time were also mentioned.
Results. Fraction time delivery (time to deliver the total dose) was 16±6min. The number of KV images acquired during VMAT
delivery is 26±15 with a maximum of 64. Average deviation in cranio caudal direction was analyzed on each images resulting in
a mean deviation of 0.29 [0–1.4]mm. Antero posterior or lateral shifts are difﬁcult to analyzed in a post processing phase as they
are not visible on all KV images but online correction with a shift of ﬁducial outside the green circles was necessary for only 2
sessions on 120.
Conclusion. IntrafractionKVveriﬁcation is possiblewith the IMRsystemavailable onTruebeam. Increase in time sessionacceptable
even if the process must actually be associate to a respiratory gate treatment. New version of the software in the next future will
allow this kind of online veriﬁcation without the need of RPM system.
http://dx.doi.org/10.1016/j.rpor.2013.03.545
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Purpose. Determine the impact of treatment with SBRT with curative intent in the evolution of the disease in oligometastastatic
patients treated in our center.
Methods. Between 2008 and 2012, 7 patients with less than 5 metastatic lesions and primary controlled were enrolled on prospec-
tive studies of SBRT for oligometastases. All available records were retrospectively reviewed to determine the evolution of the
disease. The hystologies were: 1 endometrium, 1 breast cancer, 2 prostate, 2 GI ADC, 1 NSCLC. The location of oligometastasis
were: 2 spine, 4 bone, 1 liver, 2 lung, 1 retroperitoneum. All patients has ECOG 0-1. The median age was 64 years, median time
from diagnosis of the primary diagnosis of metastases was 4.7 years. PTV volume of the lesions was between 13 cc and 55 cc,
the doses administered were 21Gy in 3 fx to 60Gy to in 5 fx. In all cases the technique was guided by CBKvCT image after CT
simulation, fusion with PET/CT and/or MRI, and calculation, 4 with 3DRTE and 3 with IMRT. The toxicity was reported with the
CTCAE.4 scale by site.
Results. With a median follow-up of 27 months (4–50), the results in terms of local control after treatment of metastases were
80% (2 local progressions and treated again with SBRT, and 1 distance progression treated with chemotherapy). All patients are
alive and maintain his ECOG at the time of the study. The improvement of symptoms was 90%. The toxicity reported in all the
patients was less than G2 in CTCAE.4 scale by site. No chronicle toxicity was reported.
Conclusions. Among this limited experience, SBRT is a good option in oligorecurrent patients, and perhaps may yield prolonged
survival, cure or chroniphy the disease in select patients with limited metastases.
http://dx.doi.org/10.1016/j.rpor.2013.03.546
